David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly

INDIANAPOLIS, May 18, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today announced that David M. Kendall, M.D., currently chief scientific and
medical officer of the American Diabetes Association, has been named
distinguished medical fellow for Lilly. He will transition from his current role
in late-July.

In his new role, Kendall will serve as a senior medical advisor for Lilly
Diabetes in advocacy and clinical science communities and as a representative to
the professional medical community. In addition, he will help provide scientific
direction for Lilly in diabetes discovery and clinical development. Other key
responsibilities will include the support of Lilly’s medical education efforts
and diabetes healthcare evaluation programs.

“David brings a critical external view, including the insights he gained while
at the American Diabetes Association,” said Enrique Conterno, president of Lilly
Diabetes. “We are working hard to gain leadership in diabetes care, and that
leadership must start with an understanding of the needs of patients and health
care providers.”

Kendall will report to Robert Heine, M.D., vice president medical affairs, Lilly
Diabetes.

“With his background as a clinician, researcher and diabetes advocate, David is
the ideal candidate for this position,” said Heine. “His focus, passion and
understanding of diabetes care will enable us to create ever better solutions
for people living with diabetes.”

About David Kendall

Kendall joins Lilly Diabetes from the American Diabetes Association, where he
serves as scientific and medical officer and has been responsible for the
oversight of the Association’s research programs, medical affairs, medical
education, international affairs, medical information and community programs
since 2009.

Kendall also is an associate professor of medicine at the University of
Minnesota and an adjunct medical director at the International Diabetes Center,
both located in Minneapolis, Minnesota.

Prior to these appointments, Kendall held a number of leadership positions at
the International Diabetes Center, and served as faculty at the University of
Minnesota Medical School.

Kendall’s experience in diabetes spans nearly 25 years, with a research focus on
the clinical management of type 1 and type 2 diabetes, emerging novel therapies
as well as the treatment and prevention of diabetes complications. He is the
author of more than 150 original manuscripts, chapters and professional reviews
and a former NIH clinical investigator for both the National Institutes of
Diabetes, Digestive and Kidney Diseases and the National Heart, Lung and Blood
Institute.

Kendall received his bachelor’s degree from St. Olaf College in Northfield,
Minnesota, and earned his M.D. and completed his post doctoral training in
Diabetes, Endocrinology and Metabolism at the University of Minnesota Medical
School in Minneapolis.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering
industry-leading solutions to support people living with and treating diabetes.
Lilly introduced the world’s first commercial insulin in 1923, and remains at
the forefront of medical and delivery device innovation to manage diabetes.
Lilly is also committed to providing solutions beyond therapy – practical tools,
education, and support programs to help overcome barriers to success along the
diabetes journey. At Lilly, the journeys of each person living with or treating
diabetes inspire ours. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information – for some of the world’s most urgent medical
needs. Additional information about Lilly is available at www.lilly.com.

P-LLY

SOURCE Eli Lilly and Company